Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 37th Annual J.P. Morgan Healthcare Conference (January 2019)
7 slides from Jazz Pharmaceuticals's conference presentation, Jan 8, 2019
Slide 1: 37th Annual J.P. Morgan Healthcare Conference
37th Annual J.P. Morgan Healthcare Conference Bruce Cozadd, Chairman and CEO | January 7, 2019 Jackie © 2019 Jazz Pharmaceuticals all rights reserved. OSA Patient
Slide 2: Forward-Looking Statements
Forward-Looking Statements “Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995 This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future financial and ope
Slide 3: A Strong Foundation To Support Global Growth
A Strong Foundation To Support Global Growth 4 >20 3 1,200 $1.9B1 Marketed R&D Innovative Experienced Revenues Products Programs Platform Employees Technologies 1 in Sleep and Multi-stage studies CombiPlex (Jazz) ~400 R&D 2018 Guidance 3 in Hematology/ in Sleep and ADC (ImmunoGen) ~400 outside U.S.
Slide 4: Transforming Investment Opportunity
Transforming Investment Opportunity DISCIPLINED CAPITAL STRONG FINANCIAL DIVERSE AND ALLOCATION TO OPTIMIZE EXECUTION GROWING PIPELINE SHAREHOLDER RETURNS • 2018G revenues of $1.9B1 • Multiple late- and mid-stage • $4.4B deployed in corporate assets development transactions • Doubling of revenues si
Slide 5: Xyrem Net Product Sales
1 • FDA-approved for the NET PRODUCT SALES treatment of cataplexy $ in millions and EDS in narcolepsy Nine months ended patients $1,500 $1,385 – $1,4002 September 30 ³ 7 years of age $1,250 $1,187 • Disease awareness $1,108 efforts to improve $1,000 narcolepsy awareness and diagnosis rates $750 • Re
Slide 6: Hematology/Oncology Revenues
Hematology/Oncology Revenues NET PRODUCT SALES1 $ in millions $250 $250 $250 $201 $197 $165- $200 $200 $145- $200 $1752 $1652 $150 $150 $134 $150 $95- $109 $1102 $100 $100 $100 $50 $50 $50 $34 $0 $0 $0 2016 2017 2018G 2016 2017 2018G 2017 2018G Nine months ended September 30 1 2016 and 2017 audited;
Slide 7: Strong Financial Execution
Strong Financial Execution TOTAL REVENUES1 NON-GAAP ADJUSTED NET INCOME NET CASH PROVIDED BY OPERATING $ in millions PER DILUTED SHARE4 ACTIVITIES1 (unaudited) $ in millions $12.75 – $1,860 – $13.252 $1,9002 $1,619 $11.04 $10.14 $1,488 $9.45 $1,325 $693 $592 $532 2015 2016 2017 2018G 2015 2016 2017
Jazz Pharmaceuticals — 37th Annual J.P. Morgan Healthcare Conference (January 2019) on 6ix